Opioid Overdose Deaths Drop Nearly 50% Since 2023 Peak, CDC Data Shows

Opioid overdose deaths in the United States have dropped by nearly half since their June 2023 peak, reaching levels not seen in nearly a decade, according to provisional data from the Centers for Disease Control and Prevention released this month.

The year ending in October 2025 saw 46,066 opioid overdose deaths nationally—barely more than half the peak of 86,075 deaths recorded in June 2023, and the lowest count since April 2017. The decline marks the most sustained reduction in overdose mortality since the modern opioid epidemic began, driven by a weaker fentanyl supply traced to Chinese crackdowns on precursor chemicals and expanded harm reduction efforts across the country.

A Historic Reversal

The CDC's National Vital Statistics System data, analyzed by Stateline, reveals that both the raw numbers and age-adjusted rates of opioid overdose deaths fell across all racial groups between 2023 and 2026. This represents a stark departure from the 2019-2023 period, when death rates declined only among white Americans while surging sharply among Black and Indigenous populations.

Even older adults—a demographic whose overdose deaths had climbed even as other groups saw improvements—experienced a 25% decline from 2023 to 2025, though this remained about half the national average reduction.

Keith Humphreys, a health policy professor at Stanford University who has testified before Congress on overdose deaths among older adults, attributes much of the decline to what he calls a "fentanyl supply shock" originating in China. The weakening supply has affected not only heroin and counterfeit pills but also cocaine contaminated with fentanyl, which had driven overdose deaths among older Black men in particular.

"This likely includes some long-term cocaine users who had the bad luck to get cocaine that had fentanyl in it," Humphreys said. White women, who are more likely to overdose on prescription drugs in suicide attempts, would be less affected by changes in the illicit fentanyl supply.

The China Connection

In a January report published in Science, Humphreys and a research team traced elevated mentions of a "drought" in fentanyl on Reddit beginning in May 2023—nearly the exact moment national overdose deaths began their sustained decline. The Drug Enforcement Administration reported parallel trends: decreasing potency in seized fentanyl, fewer overall seizures, and a dramatic drop in the percentage of pills containing lethal doses.

In fiscal year 2023, 76% of fentanyl pills seized by the DEA contained a lethal dose. By fiscal 2025, that figure had fallen to 29%. "These reductions in potency and purity correlate with a decline in synthetic opioid deaths," the DEA stated in its December assessment.

The Science report concluded that "actions by the government of China that resulted in greater scrutiny of production and export of precursor chemicals, including the removal of online advertisements and several marketplaces," likely triggered the drought. Fentanyl precursor chemicals typically originate in China, are processed into finished product in Mexico, and are then smuggled into the United States.

The fact that Canada—where fentanyl is typically produced domestically from Chinese chemicals rather than smuggled across borders—has experienced a similar drop in overdose deaths supports the theory that China's enforcement actions have had a transnational impact, regardless of individual countries' border security policies.

"Drug dealers often adapt to supply shortages by lowering purity more than raising prices," the researchers noted. Mexican fentanyl producers, facing difficulty sourcing Chinese precursors, appear to have diluted their product rather than raising street prices—inadvertently making each dose less deadly.

Regional Variations

While the national trend is unmistakably downward, regional patterns reveal persistent challenges. Ohio recorded the nation's steepest decline: a 63% drop from approximately 4,300 annual deaths in June 2023 to about 1,600 as of October 2025.

"We're seeing things you would expect—like reductions in emergency department visits and reductions in Medicaid costs," said Erin Reed, director of RecoveryOhio, the state agency tasked with reducing overdose deaths. "But we're also seeing a positive impact on violent crime and recidivism, and I think this is really, really encouraging. At the end of the day, people want to be safe."

West Virginia, Virginia, and Florida also posted significant declines. But Arizona, Alaska, and Nevada have seen deaths increase since the 2023 national peak.

Arizona's challenges are compounded by its role as a major fentanyl entry point from Mexico, dominated by the Sinaloa Cartel. In July 2024, U.S. Customs and Border Protection officers at the Port of Lukeville made the largest fentanyl seizure in the agency's history: 4 million pills hidden in a trailer driven by a 20-year-old U.S. citizen.

Recent research has also linked Arizona's notorious summer heat to exacerbated overdose deaths. Will Humble, executive director of the Arizona Public Health Association, pointed to political infighting over the state's $1.2 billion opioid settlement as a complicating factor.

"Many other states are way ahead of Arizona when it comes to distributing the state portion of the opioid settlement dollars," Humble said. "It could be there are fewer interventions because the state dollars are locked up. There's this dispute in Arizona over who gets to decide."

Colorado, meanwhile, saw an uptick in synthetic opioid deaths beginning in late 2024, despite an overall 9% decline since the 2023 national peak. A March report from the Common Sense Institute, a nonpartisan research group with Republican ties, called for stiffer penalties for fentanyl possession and distribution.

Ground-Level Interventions

While weakened supply is the primary driver of the national decline, harm reduction and treatment expansion have played critical supporting roles. Sarah Beckman, 36, works with Hamilton County's Quick Response Team in Ohio, meeting with residents shortly after they survive an overdose.

"That window is so small," Beckman said. "It has to be kind of a perfect storm for an individual to be, like, 'OK, I'm ready.'"

Beckman, who stopped using illicit drugs 11 years ago when she became pregnant, said the team expanded from two days a week to full-time coverage when overdoses surged a few years ago.

"When you're in the midst of addiction you need help with everything. For us it's just meeting people where they are and saying, 'Hey, are you hungry? Do you have enough clothes?'" Beckman said. "You're showing consistency and empathy, and by doing that you can slowly move someone closer toward accepting overdose prevention materials or hopefully, eventually, treatment."

Even when people aren't ready for formal treatment, acts of kindness can prevent the thefts and arrests that cycle individuals into the criminal justice system—as they once did for Beckman, who was charged with resisting arrest after stealing to buy drugs.

But the team is now encountering a new challenge: pills spiked with xylazine, an animal tranquilizer that causes severe addiction and withdrawal symptoms beyond those typical of opioids alone. Three recent clients survived overdoses but required emergency-level detox care.

"We can educate people in the community: 'Hey, your drugs are not what you thought they were, that's why you're experiencing all these weird side effects,'" Beckman said. "These substances are so severe that a traditional detox hasn't been able to handle them."

Fragile Progress

In their Science article, Humphreys and his co-authors cautioned that the current decline offers an opportunity that may not last.

"The incentive to restore the fentanyl trade will persist as long as there is demand for the drug," they wrote. "It may be wise to use the current drought as an opportunity to ramp up the prevention and treatment programs that have evidence of decreasing demand."

The warning comes as the nation grapples with political uncertainty around addiction funding. In January, the Trump administration abruptly terminated hundreds of Substance Abuse and Mental Health Services Administration (SAMHSA) grants—worth an estimated $2 billion—that funded overdose prevention, naloxone distribution, peer recovery support, and outreach to people experiencing homelessness and serious mental illness. After widespread outcry from advocacy groups and bipartisan congressional leaders, many grants were reinstated, but the episode underscored the fragility of federal support for harm reduction infrastructure.

Whether the current decline represents a durable turning point or a temporary respite depends on factors largely outside U.S. control: China's willingness to sustain enforcement against precursor chemical manufacturers, Mexican cartels' ability to adapt supply chains, and the emergence of new synthetic opioids or adulterants.

What remains within U.S. control is the expansion of evidence-based interventions—medication-assisted treatment, naloxone distribution, syringe services, peer support networks, and low-barrier access to care—that have proven effective at keeping people alive long enough to consider recovery.

The 46,066 deaths recorded in October represent the lowest count in nearly a decade, but they also represent 46,066 individuals, families, and communities still grappling with loss. The decline is real, measurable, and cause for cautious optimism. But as Beckman noted from the front lines in Ohio, the drugs people are using continue to evolve, and the systems designed to help them must evolve as well.